• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index.

作者信息

Basolo F, Caligo M A, Pinchera A, Fedeli F, Baldanzi A, Miccoli P, Iacconi P, Fontanini G, Pacini F

机构信息

Department of Oncology, University of Pisa, Italy.

出版信息

Thyroid. 2000 Sep;10(9):741-6. doi: 10.1089/thy.2000.10.741.

DOI:10.1089/thy.2000.10.741
PMID:11041450
Abstract

Cyclin D1 is a G1 cyclin participating in the control of cell cycle progression through interaction with the retinoblastoma gene product (pRB). The overexpression of positive regulators (such as cyclin D1) has been reported in a variety of neoplasms, but their role in thyroid tumorigenesis is yet to be established. In our series of 54 thyroid carcinomas, cyclin D1 overexpression (detected by both immunohistochemistry and by Northern blotting) was correlated with prognostic variables, proliferative activity and pRB. Cyclin D1 overexpression was observed in 35% of thyroid carcinomas with a significantly higher expression of this cyclin in neoplastic tissues than in matched normal parenchyma. In well-differentiated carcinomas, the cyclin D1 mRNA overexpression was inversely correlated with nodal status (p = 0.03), while the protein product was higher in tumors from patients less than 40 than patients over 40 years of age. Inversely, there was no significant correlation with gender and tumor status, pRB and with proliferative activity.

摘要

相似文献

1
Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index.
Thyroid. 2000 Sep;10(9):741-6. doi: 10.1089/thy.2000.10.741.
2
Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity.视网膜母细胞瘤基因产物(pRb)在套细胞淋巴瘤中的表达。与细胞周期蛋白D1(PRAD1/CCND1)mRNA水平及增殖活性的相关性。
Am J Pathol. 1996 May;148(5):1591-600.
3
Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.细胞周期蛋白D1、E2F-1和Ki-67在甲状腺良恶性病变中的免疫组化表达
J Pathol. 2002 Oct;198(2):157-62. doi: 10.1002/path.1185.
4
Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas.
Endocrine. 1998 Feb;8(1):61-4. doi: 10.1385/ENDO:8:1:61.
5
Cyclin D1 expression in primary thyroid carcinomas.原发性甲状腺癌中细胞周期蛋白D1的表达
Neuro Endocrinol Lett. 2005 Dec;26(6):815-8.
6
The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer.细胞周期调节蛋白细胞周期蛋白D1在甲状腺癌进展中的作用。
Mod Pathol. 2000 Aug;13(8):882-7. doi: 10.1038/modpathol.3880157.
7
Cyclin D1 protein expression in human thyroid gland and thyroid cancer.细胞周期蛋白D1在人甲状腺及甲状腺癌中的蛋白表达
Anat Histol Embryol. 2006 Apr;35(2):125-9. doi: 10.1111/j.1439-0264.2005.00648.x.
8
Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.细胞周期蛋白D1在原发性乳腺癌中的表达与扩增:与组织病理学类型及临床病理参数的关系
Oncol Rep. 2002 Mar-Apr;9(2):409-16.
9
Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.细胞周期蛋白D1在恶性潜能不确定的高分化甲状腺肿瘤中的表达
Diagn Pathol. 2015 Apr 18;10:32. doi: 10.1186/s13000-015-0262-8.
10
Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification.细胞周期蛋白D1蛋白表达可预测甲状腺微小乳头状癌的转移行为,但与基因扩增无关。
J Clin Endocrinol Metab. 2002 Apr;87(4):1810-3. doi: 10.1210/jcem.87.4.8352.

引用本文的文献

1
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.CDK4 磷酸化状态与 CDK4/6 和 BRAF/MEK 抑制联合应用于晚期甲状腺癌的合理选择。
Front Endocrinol (Lausanne). 2023 Oct 26;14:1247542. doi: 10.3389/fendo.2023.1247542. eCollection 2023.
2
Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma.将细胞周期蛋白D1作为甲状腺乳头状癌的一种治疗方法。
Front Oncol. 2023 Jun 22;13:1145082. doi: 10.3389/fonc.2023.1145082. eCollection 2023.
3
Immunohistochemical Biomarkers in Thyroid Pathology.
甲状腺病理学中的免疫组织化学标志物。
Endocr Pathol. 2018 Jun;29(2):91-112. doi: 10.1007/s12022-018-9532-9.
4
SOST silencing promotes proliferation and invasion and reduces apoptosis of retinoblastoma cells by activating Wnt/β-catenin signaling pathway.SOST基因沉默通过激活Wnt/β-连环蛋白信号通路促进视网膜母细胞瘤细胞的增殖和侵袭并减少其凋亡。
Gene Ther. 2017 Jul;24(7):399-407. doi: 10.1038/gt.2017.31. Epub 2017 Jun 15.
5
Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.甲状腺乳头状癌中差异表达激酶的鉴定及潜在抗癌药物的筛选
Dis Markers. 2016;2016:2832980. doi: 10.1155/2016/2832980. Epub 2016 Sep 15.
6
Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma.全基因组表达分析表明基质金属蛋白酶通路失调在未分化甲状腺癌中起关键作用。
BMC Genomics. 2015 Mar 18;16(1):207. doi: 10.1186/s12864-015-1372-0.
7
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.p53通过抑制mTOR信号通路的激活来抑制癌进展。
Oncogene. 2015 Jan 29;34(5):589-99. doi: 10.1038/onc.2013.589. Epub 2014 Jan 27.
8
Effects of the Smad4 C324Y mutation on thyroid cell proliferation.Smad4 C324Y 突变对甲状腺细胞增殖的影响。
Int J Oncol. 2013 Jun;42(6):1890-6. doi: 10.3892/ijo.2013.1908. Epub 2013 Apr 17.
9
Role of estrogen in thyroid function and growth regulation.雌激素在甲状腺功能及生长调节中的作用。
J Thyroid Res. 2011;2011:875125. doi: 10.4061/2011/875125. Epub 2011 May 4.
10
Occult thyroid carcinoma.隐匿性甲状腺癌。
Acta Otorhinolaryngol Ital. 2009 Dec;29(6):296-304.